New hope for tough psoriasis spots: tildrakizumab under the microscope
NCT ID NCT05938361
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well tildrakizumab works for psoriasis in areas that are often hard to treat, like the scalp, nails, genitals, and palms. About 120 adults with moderate to severe psoriasis will receive tildrakizumab and be followed for up to 52 weeks. The goal is to see if the drug improves these stubborn spots and overall quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tildrakizumab (an injected antibody that blocks IL-23 to reduce inflammation)
- What this could lead to
- If successful, this could show that tildrakizumab is a good option for treating psoriasis in areas that are usually hard to manage, like the scalp, nails, genitals, and palms.
- What could go wrong
- This is a single-arm study with no placebo group, so results may be less reliable. It is also relatively small (120 people) and only follows participants for 52 weeks, so long-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Oct 2025
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a diagnosis of moderate to severe chronic plaque psoriasis with specific difficult-to-treat locations.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient with a diagnosis of moderate to severe chronic plaque psoriasis documented in the medical record, 2. Disease diagnosis \> 6 months (regardless of severity at diagnosis) 3. Involvement of at least one of the following areas: nails, scalp, genital, palmoplantar (non-pustular) 4. Indication for treatment by IL-23 inhibitor. Tildrakizumab must be the selected IL-23 inhibitor therapy prior to enrolling the patient in the study. Patients who have previously received previous treatment by IL-23 inhibitors may be included. 5. Patient 18 years of age or older at the inclusion visit 6. French social security beneficiary Exclusion Criteria: 1. Patient unable to comply with study requirements (i.e.complete study questionnaires) 2. Patient who, in the opinion of the investigator, should not participate in the study. This opinion should be documented in the patient's record. 3. Patient included in an interventional clinical trial at inclusion. 4. Vulnerable patient or patient under court protection 5. Patients with known hypersensitivity to IL-23 inhibitors 6. Patients with HIV or active HBV or HCV infection at the time of inclusion 7. Patient with a history of untreated latent tuberculosis or active tuberculosis at inclusion 8. Patient with any other serious active infection present at inclusion that contraindicates IL23 inhibitors use. 9. Pregnant or lactating woman
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psoriasis genital are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Dermatologie- Hopital Saint Joseph
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.